NasdaqCM:SNGX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Soligenix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SNGX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-13.3%

SNGX

0.2%

US Biotechs

2.8%

US Market


1 Year Return

180.0%

SNGX

25.7%

US Biotechs

9.3%

US Market

Return vs Industry: SNGX exceeded the US Biotechs industry which returned 25.7% over the past year.

Return vs Market: SNGX exceeded the US Market which returned 9.3% over the past year.


Shareholder returns

SNGXIndustryMarket
7 Day-13.3%0.2%2.8%
30 Day28.1%9.1%8.9%
90 Day-38.2%11.9%-0.5%
1 Year180.0%180.0%26.9%25.7%11.8%9.3%
3 Year-17.3%-17.3%34.8%30.3%31.4%22.7%
5 Year-88.3%-88.3%-2.5%-8.3%58.7%40.9%

Price Volatility Vs. Market

How volatile is Soligenix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Soligenix undervalued compared to its fair value and its price relative to the market?

14.38x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SNGX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SNGX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SNGX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SNGX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SNGX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SNGX is overvalued based on its PB Ratio (14.4x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is Soligenix forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

66.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNGX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: SNGX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SNGX's is expected to become profitable in the next 3 years.

Revenue vs Market: SNGX's revenue (56.3% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: SNGX's revenue (56.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SNGX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Soligenix performed over the past 5 years?

-15.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SNGX is currently unprofitable.

Growing Profit Margin: SNGX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SNGX is unprofitable, and losses have increased over the past 5 years at a rate of -15.2% per year.

Accelerating Growth: Unable to compare SNGX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SNGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: SNGX has a negative Return on Equity (-435.25%), as it is currently unprofitable.


Next Steps

Financial Health

How is Soligenix's financial position?


Financial Position Analysis

Short Term Liabilities: SNGX's short term assets ($9.6M) exceed its short term liabilities ($6.3M).

Long Term Liabilities: SNGX's short term assets ($9.6M) exceed its long term liabilities ($4.2K).


Debt to Equity History and Analysis

Debt Level: SNGX is debt free.

Reducing Debt: SNGX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SNGX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SNGX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.2% each year


Next Steps

Dividend

What is Soligenix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SNGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SNGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SNGX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SNGX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SNGX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Christopher Schaber (53yo)

13.83yrs

Tenure

US$688,149

Compensation

Dr. Christopher J. Schaber, Ph.D., has been the President and Chief Executive Officer at Soligenix, Inc. (Formerly DOR BioPharma Inc.) since August 30, 2006. Dr. Schaber has more than 23 years experience i ...


CEO Compensation Analysis

Compensation vs Market: Christopher's total compensation ($USD688.15K) is about average for companies of similar size in the US market ($USD593.36K).

Compensation vs Earnings: Christopher's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Schaber
Chairman13.83yrsUS$688.15k0.20% $104.1k
Jonathan Guarino
Senior VP0.75yrUS$274.90kno data
Oreola Donini
Senior VP & Chief Scientific Officer5.5yrsUS$339.10kno data
Richard Straube
Senior VP & Chief Medical Officer6.42yrsUS$278.66kno data
Richard Dunning
Executive Officerno datano datano data

6.0yrs

Average Tenure

53yo

Average Age

Experienced Management: SNGX's management team is seasoned and experienced (6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christopher Schaber
Chairman13.83yrsUS$688.15k0.20% $104.1k
Jerome Zeldis
Independent Director9yrsUS$80.00k0.086% $44.9k
Gregory Lapointe
Independent Director11.25yrsUS$79.86k0.028% $14.5k
Robert Rubin
Independent Director10.67yrsUS$82.50k0.017% $8.6k
Dorothy Mary Keefe
Member of Oral Mucositis Medical Advisory Boardno datano datano data
Jeffrey Hyams
Member of Pediatric Crohn's Disease Medical Advisory Boardno datano datano data
James Markowitz
Member of Pediatric Crohn's Disease Medical Advisory Boardno datano datano data
Joel Rosh
Member of Pediatric Crohn's Disease Medical Advisory Boardno datano datano data
Alain Rook
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno datano datano data
Mark Schubert
Member of Oral Mucositis Medical Advisory Boardno datano datano data

10.7yrs

Average Tenure

64.5yo

Average Age

Experienced Board: SNGX's board of directors are seasoned and experienced ( 10.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44%.


Top Shareholders

Company Information

Soligenix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Soligenix, Inc.
  • Ticker: SNGX
  • Exchange: NasdaqCM
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$52.090m
  • Shares outstanding: 26.58m
  • Website: https://www.soligenix.com

Number of Employees


Location

  • Soligenix, Inc.
  • 29 Emmons Drive
  • Suite B-10
  • Princeton
  • New Jersey
  • 8540
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SNGXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 1987

Biography

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn’s disease and acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; and ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/02 12:06
End of Day Share Price2020/06/01 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.